THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

22 September 2025

Belluscura plc

("Belluscura" or the "Company")

Update regarding Proposed Funding

Board changes

Belluscura plc (AIM:BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that, further to the statement issued on 12 September 2025, discussions with Omaha Value, Inc. and a connected company called AI Ventures, Inc, regarding the proposed fundraising, have not yet been concluded as anticipated. Discussions have continued, however, with Omaha Value, Inc, AI Ventures, Inc and other potential investors with a view to the refinancing of Belluscura and Belluscura LLC, the Company's main trading subsidiary.

As a result, Belluscura LLC has taken steps to enable it to meet its immediate cash requirements.  Whilst the senior management team and those employees responsible for Sales and Shipping have been retained, to ensure the continued fulfilment of customer orders, the employment contracts of 15 of Belluscura LLC's 25 employees in the United States have been terminated.

Board changes

The Company also announces that Bob Rauker remains CEO of Belluscura LLC but has resigned from the board of Belluscura with immediate effect.

Ric Piper, who has been a Director of Belluscura since its AIM flotation in 2021, has also resigned as a non-executive director of Belluscura with immediate effect.

The ongoing funding discussions mean that the Company is still not yet able to finalise the 2024 Annual Report and Accounts and as a result trading in the Company's shares on AIM remains suspended.

A further announcement will be made in due course.

For further information please contact: